New obesity drug CRB-913 enters human testing
NCT ID NCT07310901
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tests an experimental drug called CRB-913 in people with obesity. The goal is to see if it is safe, how the body processes it, and whether it helps with weight loss. The study has two parts: one measures drug levels in healthy adults, and the other compares three doses of CRB-913 to a placebo in 252 participants over 12 weeks. Participants must be obese but otherwise healthy, and those who have recently used other weight-loss medications are not eligible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESE BUT OTHERWISE HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Accel Research Sites
RECRUITINGDeLand, Florida, 32720, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Alliance Clinical
RECRUITINGLas Vegas, Nevada, 89109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Arizona Clinical Trials
RECRUITINGChandler, Arizona, 85225, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Central Alabama Research
RECRUITINGBirmingham, Alabama, 35209, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Flourish Research
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Louisville Metabolic and Atherosclerosis Research Center
RECRUITINGLouisville, Kentucky, 40213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Lucas Research
RECRUITINGMorehead City, North Carolina, 28557, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Medpace Clinical Pharmacology
RECRUITINGCincinnati, Ohio, 45227, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Neurobehavioral Research
RECRUITINGCedarhurst, New York, 11516, United States
Contact
Contact Phone: •••-•••-••••
-
Prospective Research Innovations
RECRUITINGRancho Cucamonga, California, 91730, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Quotient Sciences
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rochester Clinical Research
RECRUITINGRochester, New York, 14609, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tampa Bay Medical Research
RECRUITINGLargo, Florida, 33761, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Velocity Clinical Research
RECRUITINGCleveland, Ohio, 44122, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Velocity Clinical Research
RECRUITINGDallas, Texas, 75230, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.